Bristol-myers Squibb Compnay

Hannguang J Chao

R Michael Lawrence

Michael C Myers

Huji Tuerdi

Heather J Finlay

Jennifer X Qiao

Wei Meng

Tammy C Wang

Timur Gungor

Rejean Ruel

William R Ewing

Joseph Anthony Tino

James A Johnson

Soong-Hoon Kim

James J Li

Jacques Y Roberge

Charles G Clark

Patrick Y S Lam

Ji Jiang

Timothy F Herpin

Carl Thibeault

Alexandre L'Heureux

Robert P Rehfuss

Gilles Bouthillier

Monique Phillips

Yalei Liu

Dora M Schnur

Wu Yang

James Clifford Sutton

George O Tora

Ellen K Kick

Michael R Lawrence

Shun Su

Adam James Clarke

Patrick YS Lam

Timothy Herpin

Jacques Yves Roberge

Alexandre L L'HEUREUX

The present invention provides compounds of Formula (I): wherein all variables are as defined in the specification, and compositions comprising any of such novel compounds. These compounds are APJ agonists which may be used as medicaments.

Apelin receptor agonists and methods of use

The present invention provides compounds of Formula (I): wherein all variables are as defined in the specification. The compounds are apelin and APJ agonists for treating cardiovascular diseases. Preferred compounds are 2-(1,1'-biphe-1H-benzo[d]imidazole derivatives. The invention further provides compositions comprising the compounds and the compounds for use in methods of medical treatment. 

2-(1,1'-biphenyl)-1H-benzodimidazole derivatives and related compounds as apelin and APJ agonists for treating cardiovascular diseases

The present invention provides compounds of Formula (I): wherein all variables are as defined in the specification, and compositions comprising any of such novel compounds. These compounds are APJ agonists which may be used as medicaments. 

2,4-dihydroxy-nicotinamides as APJ agonists

4-hydroxy-3-(heteroaryl)pyridine-2-one APJ agonists

The present invention provides novel urea mimics and analogues of Formula (I): or a stereoisomer, tautomer, pharmaceutically acceptable salt or solvate form thereof, wherein the variables A, B, W, and Rare as defined herein. These compounds are selective inhibitors of the human P2Yreceptor which can be used as medicaments.

[object Object]

A compound of formula I wherein A, X, q, R, R, R, R, R, and Rare defined herein.

LXR modulators

The present invention provides novel pyridyl or phenyl ureas and analogues thereof, which are selective inhibitors of the human P2Yreceptor. The invention also provides for various pharmaceutical compositions of the same and methods for treating diseases responsive to modulation of P2Yreceptor activity.

The present invention provides novel ureas containing N-aryl or N-heteroaryl substituted heterocycles and analogues thereof, which are selective inhibitors of the human P2Yreceptor. The invention also provides for various pharmaceutical compositions of the same and methods for treating diseases responsive to modulation of P2Yreceptor activity.

A method is provided for treating disorders of gastrointestinal motility which include the steps of administering to a patient in need of treatment of a compound having the structure or a pharmaceutically acceptable salt thereof, a prodrug ester thereof, and all stereoisomers thereof,  New compounds for use in treating disorders of gastrointestinal motility are also provided.

Compounds useful as motilin agonists and method

Compounds are provided which are useful in treating disorders of gastrointestinal motility and which have the structure or a pharmaceutically acceptable salt thereof, a prodrug ester thereof, and all stereoisomers thereof,  A method for using such compounds for treating disorders of gastrointestinal motility is also provided.

Growing community of inventors

Lawrenceville, NJ, United States of America

Hannguang J Chao